Phanes Therapeutics is an innovative drug discovery company that develops therapies to treat solid tumors and eye diseases. Founded in July 2016, Phanes has a leadership team of industry veterans with extensive drug discovery and development experience in the global pharma and biotech industry, including Pfizer, Amgen, J&J, ICON, and CrownBio.
Our first-in-class molecules include a monoclonal antibody for solid tumors as well as age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The best-in-class molecules in our pipeline are designed to deliver clinically meaningful differentiation in safety or efficacy. Our innovation is also reflected by several lead molecules in the bispecific antibody and single-chain variable fragment (scFv) programs in our pipeline.
Our mission is to become an important source of innovative molecules and deliver some of the most robust therapies to improve patients’ lives.
Session ID: 560677